{"title": "NewsRamp Curated News Feed for Science", "description": "NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.", "site_url": "https://www.newsramp.com", "display_name": "NewsRamp.com", "next_page": "https://feeds.newsramp.net/tldr/newsramp/moderated/10/2/science.json", "instructions": "Fine tune the feed as follows /tldr/category/newsramp/en/all/20/1/science.json /tldr/category/en/[all/moderated]/[records per page up to 100]/[page number]/science.json - Available Language Codes English=en", "prev_page": "", "current_page": 1, "total_records": 2868, "total_pages": 287, "image_url": "https://newsramp.com/light-logo.svg", "language": "en", "ttl": 10, "news": [{"feed_item_id": 35248, "prhash_id": "67c89835998f993af82e1513712fa739", "headline": "Gut Microbiome Emerges as Key Player in Cancer Therapy Revolution", "content": "        <article>        <h1>Gut Microbiome Emerges as Key Player in Cancer Therapy Revolution</h1>        <img src='https://cdn.newsramp.app/banners/science-5.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Gut Microbiome Emerges as Key Player in Cancer Therapy Revolution'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Manipulating the gut microbiome offers a competitive edge in cancer therapy by enhancing immunotherapy efficacy and enabling early detection via non-invasive stool tests.</li>            <li>Mechanistic reviews in Cancer Biology & Medicine detail how microbial metabolites, dysbiosis, and tumor-resident bacteria influence cancer progression and treatment response through multi-omics integration.</li>            <li>Harnessing the microbiome as a therapeutic partner promises more personalized, less invasive cancer care, potentially improving survival and quality of life for patients worldwide.</li>            <li>Tumor-resident bacteria can serve as diagnostic biomarkers and convert 'cold' tumors into 'hot' ones responsive to checkpoint inhibitors, opening a new frontier in oncology.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it reveals a paradigm shift in cancer treatment: the microbiome is not just a bystander but a potential therapeutic target. Understanding how gut and tumor-resident bacteria influence cancer progression and treatment response opens avenues for non-invasive diagnostics, personalized probiotics, and microbiome-based therapies that could enhance immunotherapy efficacy, reduce side effects, and improve outcomes for patients with various cancers, including colorectal, liver, gastric, and pancreatic cancers. For the general public, it underscores the importance of gut health in cancer prevention and treatment, potentially leading to new dietary and probiotic recommendations.</p>        <h2>Summary</h2>        <p><p>The gut microbiome is increasingly recognized as a key driver of cancer development, progression, and treatment response, according to recent research published in a special issue of <a href='https://www.cancerbiomed.org/content/23/5'>Cancer Biology & Medicine</a>. Guest-edited by Professor Jun Yu from The Chinese University of Hong Kong, the collection includes seven review articles covering hepatocellular carcinoma, colorectal cancer, gastric cancer, and pancreatic ductal adenocarcinoma. The articles explore how microbial dysbiosis\u2014loss of beneficial bacteria like Lactobacillus and Akkermansia and overgrowth of pathogens such as Klebsiella pneumoniae\u2014fuels hepatocarcinogenesis through chronic inflammation. A multi-omics framework for colorectal cancer integrates metagenomics, transcriptomics, and metabolomics to identify actionable targets. Probiotics are highlighted as promising adjuncts to conventional therapy, restoring gut barrier function and modulating immune responses. Tumor-resident bacteria emerge as diagnostic and prognostic biomarkers, influencing therapeutic outcomes. Additional reviews cover animal models for gastric cancer, the microbiome's role in pancreatic cancer, and how microbial metabolites modulate immunogenic cell death, potentially converting 'cold' tumors into 'hot' ones responsive to checkpoint inhibitors.</p><p>The authors emphasize that the next phase of cancer research requires integrating genetics, immunology, and microbiology, treating the microbiome as an integral component of the tumor ecosystem. Interventions such as fecal microbiota transplantation, engineered bacteria, or metabolite-based drugs must be designed with this holistic view. Microbiome-derived biomarkers could enable early detection of gastrointestinal cancers through non-invasive stool tests. Probiotic formulations tailored to individual gut profiles might boost immune checkpoint inhibitor efficacy while reducing adverse events. For bacteria-infected tumors, targeted antimicrobial or nanodrug strategies could simultaneously combat infection and malignancy. As these approaches mature, the line between diagnosis, treatment, and prevention blurs, moving cancer care toward precision medicine where the microbiome becomes an indispensable guide.</p><p>For more details, access the full special issue at <a href='https://www.cancerbiomed.org/content/23/5'>https://www.cancerbiomed.org/content/23/5</a>. The journal <a href='https://www.cancerbiomed.org/'>Cancer Biology & Medicine</a> is a peer-reviewed open-access journal sponsored by China Anti-cancer Association and Tianjin Medical University Cancer Institute & Hospital, indexed in SCOPUS, MEDLINE, and SCI (IF 12.4).</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/67c89835998f993af82e1513712fa739.35248.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/67c89835998f993af82e1513712fa739.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://24-7pressrelease.com'>24-7 Press Release</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/24-7PressRelease/en/microbiome-and-cancer-from-passive-bystanders-to-active-players/67c89835998f993af82e1513712fa739'>Gut Microbiome Emerges as Key Player in Cancer Therapy Revolution.</a></p></div>        </article>    ", "published": "2026-07-11T07:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/67c89835998f993af82e1513712fa739.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/67c89835998f993af82e1513712fa739.webp", "enclosure": "https://cdn.newsramp.app/banners/science-5.jpg", "site_handle": "24-7PressRelease", "seo_description": "Discover how the gut microbiome drives cancer progression and therapy response. A special issue in Cancer Biology & Medicine reveals microbial mechanisms, probiotics, and tumor-resident bacteria as new targets for precision oncology.", "newsramp_curated": "https://newsramp.com/curated-news/gut-microbiome-emerges-as-key-player-in-cancer-therapy-revolution/67c89835998f993af82e1513712fa739"}, {"feed_item_id": 35243, "prhash_id": "35f97fbeb5ca9b2e645faf3cd812a1d6", "headline": "Climate Change Fuels Antimicrobial Resistance via Animal Diseases", "content": "        <article>        <h1>Climate Change Fuels Antimicrobial Resistance via Animal Diseases</h1>        <img src='https://cdn.newsramp.app/banners/environment-energy-6.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Climate Change Fuels Antimicrobial Resistance via Animal Diseases'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Using climate data and genomic surveillance, groups can identify high-risk AMR periods to stay ahead of outbreaks.</li>            <li>Climate change increases Salmonella ARG abundance by 10% via heat and flooding; low emissions plus stewardship can cut 24%.</li>            <li>Integrating climate, animal health, and antibiotic stewardship protects vulnerable regions from rising antimicrobial resistance.</li>            <li>A 38% rise in Salmonella resistance genes from 1940-2023 was found in 488,232 genomes across 139 countries.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it reveals a hidden link between climate change and antimicrobial resistance (AMR), showing that global warming and extreme weather can accelerate the spread of drug-resistant bacteria through animals and the environment. For the public, it means that efforts to combat AMR must now include climate action and animal health monitoring, as traditional antibiotic stewardship alone may not suffice. The findings urge policymakers to integrate climate data into surveillance systems, which could directly impact food safety, disease prevention, and the effectiveness of last-resort antibiotics worldwide.</p>        <h2>Summary</h2>        <p><p>As climate change reshapes the conditions in which pathogens survive and move, antimicrobial resistance is no longer only a question of antibiotic use. A new editorial places animal diseases at the center of this emerging risk, arguing that warming, floods, intensive farming, wastewater, and food systems can connect resistant bacteria across animals, environments, and people. Using non-typhoidal Salmonella as a sentinel, the article sets out a One Health framework for understanding how climate pressures may weaken ecological barriers that once helped contain antimicrobial resistance. A companion global genomic study of Salmonella adds quantitative evidence, showing why climate-informed surveillance is becoming urgent for farms, ecosystems, and public health.</p><p>Antimicrobial resistance (AMR) has traditionally been addressed through antimicrobial stewardship, infection control, and better prescribing. These measures remain essential, but animal-disease systems are increasingly exposed to pressures that do not fit within a single sector. Rising temperatures can favor bacterial growth and horizontal gene transfer (HGT), while extreme precipitation can disperse antimicrobial resistance genes (ARGs) through agricultural runoff, sewage, rivers, and food chains. Zoonotic pathogens such as Salmonella move naturally across these interfaces, making them useful indicators of wider human\u2013animal\u2013environment risks. Based on these challenges, in-depth research is needed into climate-driven AMR transmission in animal diseases under a One Health framework.</p><p><a href='https://doi.org/10.1186/s44149-026-00255-5' rel='nofollow'>Published (DOI: 10.1186/s44149-026-00255-5)</a> on June 29, 2026, in <a href='https://link.springer.com/journal/44149' rel='nofollow'>Animal Diseases</a>, the editorial <strong>'Climate change and AMR in animal diseases: a one health perspective on emerging global risks'</strong> comes from the Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences. Rather than presenting climate change and antimicrobial resistance (AMR) as parallel crises, the editorial connects them through animal disease ecology and the One Health framework. It is further supported by a related research article published in The Lancet Planetary Health in 2026, which examined how climate change is associated with the global spread of antimicrobial resistance genes (ARGs) in Salmonella.</p><p>The editorial's central contribution is a practical risk map. It describes a One Health\u2013climate convergence nexus in which non-typhoidal Salmonella and ARGs circulate among hospitals, intensive agriculture, sewage treatment systems, watersheds, farms, food products, and retail environments. Climate change can intensify this loop through two immediate routes: heat-related physiological effects on bacteria and weather-driven movement of contaminated water. The article further raises the possibility that climate stress may influence pathogen adaptation in production systems, although it treats this as a hypothesis that has been extensive documented in his group (see additional references below) requiring broader validation. The companion Lancet Planetary Health study supplies the empirical backbone for this warning. Researchers analyzed 488,232 Salmonella genomes from 139 countries or regions across 1940\u20132023 and found that global average ARG abundance in Salmonella increased by 38%. Climate change was associated with a 10% rise increase in ARG abundance, with increases in 82 of 100 countries analyzed. Future modelling suggested that low-emission pathways, when combined with strengthened antibiotic stewardship, could reduce Salmonella ARGs by 24% compared with high-emission scenarios. In the editorial, these findings support a three-part response: climate-informed genomic surveillance, targeted animal-health interventions, and integrated cross-sectoral policies that can move AMR control from isolated programs to coordinated prevention across climate, livestock, environment, and health systems.</p><p>The authors said the work calls for a shift from reacting to resistant AMR-associated infections to anticipating where resistance AMR risks may intensify. They said antimicrobial stewardship remains the foundation of AMR control, but it should be paired with climate data, animal-health monitoring, and environmental surveillance. In their view, One Health should guide practical decisions\u2014from where genomes are sequenced to how farms, wastewater systems, and food-safety programs are prepared for climate extremes. The goal is to protect antimicrobial effectiveness before climate pressures widen existing gaps.</p><p>The editorial-led framework offers clear entry points for policy and practice. Veterinary services can use climate signals to identify high-risk periods for animal-disease outbreaks and resistant AMR-associated infections. Public-health agencies can connect genomic surveillance with rainfall, temperature, wastewater, livestock, and antimicrobial-use data. Food-safety systems can strengthen monitoring after floods, heat waves, and other disruptions that may mobilize resistant bacteria. For low- and middle-income countries, the papers also highlights the need for affordable sequencing, trained personnel, and fair data-sharing agreements. Most importantly, the work suggests that climate mitigation, animal health, sanitation, and antibiotic stewardship should be treated as one interconnected investment in global health security, especially in regions where climate vulnerability and AMR burden overlap.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/35f97fbeb5ca9b2e645faf3cd812a1d6.35243.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/35f97fbeb5ca9b2e645faf3cd812a1d6.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://24-7pressrelease.com'>24-7 Press Release</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/24-7PressRelease/en/climate-change-may-be-reshaping-the-fight-against-amr-in-animal-diseases/35f97fbeb5ca9b2e645faf3cd812a1d6'>Climate Change Fuels Antimicrobial Resistance via Animal Diseases.</a></p></div>        </article>    ", "published": "2026-07-11T07:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/35f97fbeb5ca9b2e645faf3cd812a1d6.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/35f97fbeb5ca9b2e645faf3cd812a1d6.webp", "enclosure": "https://cdn.newsramp.app/banners/environment-energy-6.jpg", "site_handle": "24-7PressRelease", "seo_description": "Climate change is driving antimicrobial resistance in animal diseases, warns a new editorial in Animal Diseases. A study of 488,232 Salmonella genomes shows ARGs rising with warming, urging One Health action.", "newsramp_curated": "https://newsramp.com/curated-news/climate-change-fuels-antimicrobial-resistance-via-animal-diseases/35f97fbeb5ca9b2e645faf3cd812a1d6"}, {"feed_item_id": 35228, "prhash_id": "97213f1b5b8ec497df9ceeb25bd55d9a", "headline": "Greenland Mines Secures Australian Patent for Klotho Gene Therapy", "content": "        <article>        <h1>Greenland Mines Secures Australian Patent for Klotho Gene Therapy</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-5.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Greenland Mines Secures Australian Patent for Klotho Gene Therapy'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Greenland Mines' new Australian patent strengthens its Klotho gene therapy platform, potentially boosting its competitive edge in ALS treatment.</li>            <li>The patent covers gene therapy constructs, stem cells, and delivery systems for expressing human Klotho protein to treat neuromuscular diseases.</li>            <li>This advancement offers hope for ALS patients by targeting the root cause of neuromuscular degeneration through gene therapy.</li>            <li>Klotho protein, linked to longevity, is now being harnessed in gene therapy to fight ALS and other muscle disorders.</li>        </ul>        <h2>Why it Matters</h2>        <p>This patent is crucial as it protects a promising gene therapy for ALS and other neuromuscular diseases, potentially offering new hope to patients. For investors, it strengthens Greenland Mines' IP portfolio, enhancing its valuation in both biotech and mining sectors. The development also underscores the growing convergence of advanced therapies and resource companies, positioning Greenland Mines as a unique player in the market.</p>        <h2>Summary</h2>        <p><p>Greenland Mines (NASDAQ: GRML) has announced a significant milestone in its biotechnology division, securing Australian Patent No. 2023252508 from IP Australia. This patent covers gene therapy technology exclusively licensed by the company for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent bolsters Greenland Mines' intellectual property for its Klotho-based therapeutic platform, including claims on gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. This development supports the advancement of the KLTO-202 program, which targets amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. The company's strategy involves building a multi-asset platform with exposure to rare earth materials and precious metals, while advancing its broader North Atlantic Critical Metals Corridor vision.</p><p>Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: Mining, focused on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project, and Biotech, including the Klotho gene therapy platform. The patent strengthens the company's position in both sectors, offering potential treatments for devastating diseases like ALS. The company's newsroom provides the latest updates on GRML, and the full press release is available at https://nnw.fm/PVbbH. This news highlights the intersection of mining and biotechnology, showcasing Greenland Mines' innovative approach to creating value across multiple industries.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/97213f1b5b8ec497df9ceeb25bd55d9a.35228.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/97213f1b5b8ec497df9ceeb25bd55d9a.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/greenland-mines-grml-secures-australian-patent-for-klotho-gene-therapy-platform-7087634/97213f1b5b8ec497df9ceeb25bd55d9a'>Greenland Mines Secures Australian Patent for Klotho Gene Therapy.</a></p></div>        </article>    ", "published": "2026-07-10T19:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/97213f1b5b8ec497df9ceeb25bd55d9a.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/97213f1b5b8ec497df9ceeb25bd55d9a.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-5.jpg", "site_handle": "newmediawire", "seo_description": "Greenland Mines (GRML) secures Australian patent for Klotho gene therapy targeting ALS. Strengthens IP for KLTO-202 program. Learn more at Nasdaq-listed company's newsroom.", "newsramp_curated": "https://newsramp.com/curated-news/greenland-mines-secures-australian-patent-for-klotho-gene-therapy/97213f1b5b8ec497df9ceeb25bd55d9a"}, {"feed_item_id": 35227, "prhash_id": "91f3172034602e07923126ef198c3d0b", "headline": "Quantum BioPharma Advances Platform for Neurodegenerative and Metabolic Disorders", "content": "        <article>        <h1>Quantum BioPharma Advances Platform for Neurodegenerative and Metabolic Disorders</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-2.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Quantum BioPharma Advances Platform for Neurodegenerative and Metabolic Disorders'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Quantum BioPharma's diversified platform and royalty from UNBUZZD up to $250M offer multiple revenue streams and long-term growth potential.</li>            <li>The company combines clinical-stage therapeutics, wellness products, and strategic investments, leveraging licensing and partnerships to support multiple revenue streams.</li>            <li>Quantum BioPharma targets neurodegenerative, metabolic, and alcohol misuse disorders, aiming to address significant unmet medical needs and improve lives.</li>            <li>Lucid-MS, a patented compound, prevents and reverses myelin degradation in preclinical models, potentially treating multiple sclerosis.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because Quantum BioPharma is tackling major health challenges like multiple sclerosis and alcohol misuse, which affect millions worldwide. Their diversified strategy\u2014combining cutting-edge drug development with consumer wellness products\u2014could accelerate access to treatments and generate sustainable revenue. For investors, the royalty and equity structure of UNBUZZD\u2122 offers potential long-term returns. Understanding Quantum\u2019s progress helps stakeholders gauge the future of therapies in these high-need areas.</p>        <h2>Summary</h2>        <p><p>Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on developing therapies for neurodegenerative, metabolic, and alcohol misuse disorders, was recently highlighted in a detailed article. The company is advancing a diversified platform that includes clinical-stage therapeutics, consumer wellness products, and strategic investments targeting significant unmet medical needs. Quantum BioPharma\u2019s strategy combines pharmaceutical R&D with commercialization partnerships and licensing structures to create multiple potential revenue streams. Key programs include Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis, and UNBUZZD\u2122, a consumer wellness product for alcohol misuse. Quantum spun out the OTC version of UNBUZZD\u2122 to Unbuzzd Wellness Inc., retaining a 19.84% stake and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. The company also retains full rights to develop pharmaceutical-grade alternatives. The full article can be accessed at <a href='https://ibn.fm/JtLc5'>https://ibn.fm/JtLc5</a>, and the latest news and updates are available in the company\u2019s newsroom at <a href='https://ibn.fm/QNTM'>https://ibn.fm/QNTM</a>.</p><p>Quantum BioPharma\u2019s pipeline addresses conditions with high unmet needs, such as multiple sclerosis and alcohol misuse. The company\u2019s lead compound, Lucid-MS, targets myelin degradation, a key mechanism in multiple sclerosis, and has shown promising results in preclinical studies. Meanwhile, UNBUZZD\u2122 offers a consumer-focused solution for alcohol misuse, with a unique business model that includes royalties and equity in the spin-out company. This dual approach\u2014pursuing both pharmaceutical and consumer markets\u2014positions Quantum to capture value across different stages of development and commercialization. The company\u2019s strategy also involves leveraging intellectual property and commercial relationships to drive long-term growth. For more details on the company\u2019s forward-looking statements and disclaimers, please refer to <a href='http://ibn.fm/Disclaimer'>http://IBN.fm/Disclaimer</a>.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/91f3172034602e07923126ef198c3d0b.35227.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/91f3172034602e07923126ef198c3d0b.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/why-quantum-biopharma-qntm-is-one-to-watch-7087631/91f3172034602e07923126ef198c3d0b'>Quantum BioPharma Advances Platform for Neurodegenerative and Metabolic Disorders.</a></p></div>        </article>    ", "published": "2026-07-10T18:30:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/91f3172034602e07923126ef198c3d0b.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/91f3172034602e07923126ef198c3d0b.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-2.jpg", "site_handle": "newmediawire", "seo_description": "Quantum BioPharma (NASDAQ: QNTM) advances a diversified platform targeting neurodegenerative, metabolic, and alcohol misuse disorders with clinical-stage therapeutics and consumer wellness products.", "newsramp_curated": "https://newsramp.com/curated-news/quantum-biopharma-advances-platform-for-neurodegenerative-and-metabolic-disorders/91f3172034602e07923126ef198c3d0b"}, {"feed_item_id": 35225, "prhash_id": "f5703ee50304a65f7ddc87d67a5ec160", "headline": "Nevada Organic Phosphate CEO to Discuss Strategy on Fox Business", "content": "        <article>        <h1>Nevada Organic Phosphate CEO to Discuss Strategy on Fox Business</h1>        <img src='https://cdn.newsramp.app/banners/science-3.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Nevada Organic Phosphate CEO to Discuss Strategy on Fox Business'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Nevada Organic Phosphate CEO Robin Dow will discuss the company's unique phosphate project on Fox Business, potentially boosting investor interest.</li>            <li>CEO Robin Dow will present Nevada Organic Phosphate's exploration strategy on BTV, highlighting its 6.6 km organic sedimentary phosphate bed.</li>            <li>Nevada Organic Phosphate's organic sedimentary phosphate project could support sustainable agriculture by providing a natural fertilizer source.</li>            <li>Nevada Organic Phosphate's phosphate bed is the only known large-scale organic sedimentary deposit in North America.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because Nevada Organic Phosphate's exploration of organic sedimentary phosphate could address critical supply chain needs for phosphate fertilizers, which are essential for global food production. As the only known large-scale organic sedimentary phosphate project in North America, the company's progress may reduce dependence on imported phosphate and support agricultural sustainability. Investors should monitor this development as it represents a potential opportunity in a sector vital to food security.</p>        <h2>Summary</h2>        <p><p>Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) is set to appear on Business Television (BTV) \u2013 Discover Investing Opportunities, airing on the Fox Business Channel on July 11. CEO Robin Dow will discuss the company's organic sedimentary phosphate exploration strategy, highlighting its unique position as the owner of what is believed to be the only known large-scale organic sedimentary phosphate project in North America. The project spans a 6.6-kilometer long rock phosphate bed in northeast Nevada, with additional applications extending the potential strike to over 30 kilometers. This location is strategically situated near a main highway to Montello/Elko and a rail head to California, facilitating logistics and distribution.</p><p>In addition to the television appearance, Nevada Organic Phosphate announced the approval of 300,000 stock options for certain consultants under its stock option plan. These options vest immediately, are exercisable for five years at $0.155 per share, and are subject to a four-month hold period per Canadian Securities Exchange policies. This move aligns with the company's strategy to incentivize key contributors as it advances its exploration efforts.</p><p>The news was disseminated through Rocks & Stocks, a specialized communications platform within the Dynamic Brand Portfolio of IBN. Rocks & Stocks delivers deep insights into the mining industry and provides a range of services including press release enhancement, social media distribution, and editorial syndication to over 5,000 outlets. For more details, the full press release is available at <a href='https://ibn.fm/YDa0T'>https://ibn.fm/YDa0T</a>, and the latest news and updates relating to NOP can be found in the company\u2019s newsroom at <a href='https://ibn.fm/NOP'>https://ibn.fm/NOP</a>.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/f5703ee50304a65f7ddc87d67a5ec160.35225.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/f5703ee50304a65f7ddc87d67a5ec160.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//f5703ee50304a65f7ddc87d67a5ec160'>Nevada Organic Phosphate CEO to Discuss Strategy on Fox Business.</a></p></div>        </article>    ", "published": "2026-07-10T16:40:07+00:00", "audio_release": "https://cdn.newsramp.net/audio/f5703ee50304a65f7ddc87d67a5ec160.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/f5703ee50304a65f7ddc87d67a5ec160.webp", "enclosure": "https://cdn.newsramp.app/banners/science-3.jpg", "site_handle": "ibn", "seo_description": "Nevada Organic Phosphate (CSE:NOP) CEO Robin Dow to appear on Fox Business Channel July 11 to discuss organic sedimentary phosphate exploration. Stock options approved for consultants.", "newsramp_curated": "https://newsramp.com/curated-news/nevada-organic-phosphate-ceo-to-discuss-strategy-on-fox-business/f5703ee50304a65f7ddc87d67a5ec160"}, {"feed_item_id": 35230, "prhash_id": "869ed2a42dc16376419e142a7e801ff7", "headline": "American Fusion Relocates HQ, Advances Texatron Testing and Patents", "content": "        <article>        <h1>American Fusion Relocates HQ, Advances Texatron Testing and Patents</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-5.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='American Fusion Relocates HQ, Advances Texatron Testing and Patents'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>American Fusion (AMFN) expands operations and files seven new patents, strengthening its competitive edge in fusion energy.</li>            <li>The company relocates to Fort Worth to consolidate engineering, lab, and admin functions, and targets July for initial testing.</li>            <li>By advancing fusion technology with university partnerships, American Fusion aims to provide clean, abundant energy for a better future.</li>            <li>American Fusion plans to test its 5MW and 500kW Texatron fusion engines at Texas Tech University as early as July.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it signals tangible progress in the race to commercialize fusion energy, a potentially limitless and clean power source. American Fusion's relocation to a consolidated facility and partnership with Texas Tech University could accelerate the development of its Texatron Fusion Engine, bringing us closer to a future where fusion provides safe, abundant electricity. For investors, the expansion of intellectual property and testing milestones indicate a company actively building value. For the public, each step forward in fusion technology holds the promise of transforming global energy systems, reducing reliance on fossil fuels, and combating climate change.</p>        <h2>Summary</h2>        <p><p><a href='https://www.investorbrandnetwork.com/clients/american-fusion-inc/'>American Fusion(TM) (OTC: AMFN)</a>, a developer of next-generation fusion energy technologies, has announced a series of operational and technology milestones. The company is relocating its headquarters to the Fort Worth metropolitan area as it expands engineering, laboratory, and fabrication operations. This move consolidates engineering, manufacturing, and administrative functions under one roof, streamlining operations for its Texatron(TM) Fusion Engine(TM) platforms. Management expects the new facility to enhance collaboration and accelerate development timelines.</p><p>Alongside the relocation, American Fusion is progressing toward a testing agreement with Texas Tech University for both its 5MW and 500kW Texatron(TM) Fusion Engine(TM) platforms. University testing infrastructure is expected to accelerate portions of its development program, with initial testing activities targeted as early as July. This partnership could provide critical validation and data to advance the commercialization of fusion energy, a transformative clean power source. The company also filed seven additional U.S. patent applications to expand its intellectual property surrounding the Texatron(TM) Fusion Engine(TM) architecture, bolstering its competitive position in the emerging fusion market.</p><p>These announcements highlight American Fusion's strategic push to advance from concept to reality. By co-locating operations, leveraging academic partnerships, and fortifying its IP portfolio, the company aims to position itself as a key player in the fusion energy sector. The milestones were shared via <a href='https://www.investorwire.com/'>InvestorWire</a>, a platform specializing in press release syndication for public companies. For ongoing updates, investors can visit the company\u2019s newsroom at <a href='https://ibn.fm/AMFN'>https://ibn.fm/AMFN</a>. The full details were published in a news release on <a href='https://ibn.fm/5m9td'>https://ibn.fm/5m9td</a>, with additional coverage available via the <a href='https://www.investorwire.com/news-articles/american-fusiontm-inc-amfn-expands-north-texas-operations-as-texatrontm-testing-and-patent-activity-advance/'>Read More&gt;&gt;</a> link.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/869ed2a42dc16376419e142a7e801ff7.35230.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/869ed2a42dc16376419e142a7e801ff7.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//869ed2a42dc16376419e142a7e801ff7'>American Fusion Relocates HQ, Advances Texatron Testing and Patents.</a></p></div>        </article>    ", "published": "2026-07-10T14:35:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/869ed2a42dc16376419e142a7e801ff7.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/869ed2a42dc16376419e142a7e801ff7.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-5.jpg", "site_handle": "ibn", "seo_description": "American Fusion relocates HQ to Fort Worth, expands operations for Texatron Fusion Engine. Progress toward Texas Tech testing agreement and new patent filings advance fusion energy development.", "newsramp_curated": "https://newsramp.com/curated-news/american-fusion-relocates-hq-advances-texatron-testing-and-patents/869ed2a42dc16376419e142a7e801ff7"}, {"feed_item_id": 35211, "prhash_id": "ee01667318c131626b53fced26e09f34", "headline": "Greenland Mines Secures Australian Patent for Klotho Gene Therapy", "content": "        <article>        <h1>Greenland Mines Secures Australian Patent for Klotho Gene Therapy</h1>        <img src='https://cdn.newsramp.app/banners/science-6.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Greenland Mines Secures Australian Patent for Klotho Gene Therapy'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Greenland Mines secures Australian patent for Klotho gene therapy, strengthening its IP moat in neuromuscular disease treatments.</li>            <li>Australian patent covers gene therapy constructs, stem cells, and delivery systems for expressing human Klotho protein to treat ALS.</li>            <li>This gene therapy patent advances potential treatments for ALS and neuromuscular diseases, offering hope for patients worldwide.</li>            <li>Klotho protein, known as the 'longevity gene,' may now be used in gene therapy to combat muscle-wasting diseases.</li>        </ul>        <h2>Why it Matters</h2>        <p>This patent grant strengthens Greenland Mines' intellectual property in gene therapy for neuromuscular diseases, including ALS, potentially accelerating development of treatments for conditions with high unmet need. For investors, it solidifies the company's biotech division value and may attract partnership or licensing interest, while for patients, it offers hope for novel therapies targeting fatal disorders like ALS.</p>        <h2>Summary</h2>        <p><p>Greenland Mines Ltd (NASDAQ: GRML) has announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company\u2019s Biotech Division. This patent strengthens the intellectual property supporting Greenland Mines\u2019 Klotho-based therapeutic platform, with claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. The company is a Nasdaq-listed firm with two operating divisions: Mining, focused on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project; and Biotech, including Klotho\u2019s KLTO-202 primary indication for ALS. Its strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision.</p><p>To view the full press release, visit: <a href='https://ibn.fm/PVbbH'>https://nnw.fm/PVbbH</a></p><p>NetworkNewsWire (NNW) is a specialized communications platform focusing on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team, NNW is uniquely positioned to serve companies wanting to reach a wide audience of investors, influencers, consumers, journalists and the general public. NNW brings its clients unparalleled recognition and brand awareness, cutting through information overload in today\u2019s market.</p><p>For more information, please visit <a href='https://www.networknewswire.com/'>https://www.NetworkNewsWire.com</a>. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: <a href='https://www.networknewswire.com/Disclaimer'>https://www.NetworkNewsWire.com/Disclaimer</a>.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/ee01667318c131626b53fced26e09f34.35211.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/ee01667318c131626b53fced26e09f34.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//ee01667318c131626b53fced26e09f34'>Greenland Mines Secures Australian Patent for Klotho Gene Therapy.</a></p></div>        </article>    ", "published": "2026-07-10T13:25:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/ee01667318c131626b53fced26e09f34.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/ee01667318c131626b53fced26e09f34.webp", "enclosure": "https://cdn.newsramp.app/banners/science-6.jpg", "site_handle": "ibn", "seo_description": "Greenland Mines Ltd (NASDAQ: GRML) announces Australian patent covering Klotho gene therapy for ALS and neuromuscular diseases, strengthening its biotech IP portfolio.", "newsramp_curated": "https://newsramp.com/curated-news/greenland-mines-secures-australian-patent-for-klotho-gene-therapy/ee01667318c131626b53fced26e09f34"}, {"feed_item_id": 35209, "prhash_id": "57b17c1a635e23d40a8eb30689a7e996", "headline": "MAX Power Launches Commercial Validation Drilling for Natural Hydrogen", "content": "        <article>        <h1>MAX Power Launches Commercial Validation Drilling for Natural Hydrogen</h1>        <img src='https://cdn.newsramp.app/banners/environment-energy-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='MAX Power Launches Commercial Validation Drilling for Natural Hydrogen'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>MAX Power Mining aims to be first in large-scale commercial Natural Hydrogen, offering early investors a potential first-mover advantage.</li>            <li>MAX Power mobilized Savanna Drilling Rig #416 for a multi-well program to evaluate flow, pressure, gas concentrations, and scalability.</li>            <li>Natural Hydrogen discovery supports decarbonization, potentially providing a cleaner energy source for a better tomorrow.</li>            <li>MAX Power's 1.3 million acres in Saskatchewan target subsurface Natural Hydrogen, Canada's first confirmed system.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it represents a potential paradigm shift in clean energy. Natural hydrogen, if proven commercially viable, could provide a low-cost, carbon-free energy source that is continuously generated underground, unlike green hydrogen which requires energy-intensive electrolysis. MAX Power's efforts in Saskatchewan could unlock a new domestic energy resource, reducing dependence on fossil fuels and imported hydrogen. For investors, the company's multi-well program and land position of over 1.3 million acres signal a high-risk, high-reward opportunity in a nascent sector. Success here could catalyze a global race for natural hydrogen, impacting energy markets, climate goals, and the future of sustainable fuel.</p>        <h2>Summary</h2>        <p><p>MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) has taken a significant step toward what could be a historic breakthrough in clean energy. The company mobilized Savanna Drilling Rig #416 to its Lawson Natural Hydrogen Complex in Saskatchewan, launching a multi-well commercial validation drilling program. This program targets what MAX Power believes could become the world's first large-scale commercial Natural Hydrogen discovery. The initial well will test a target identified through high-resolution 3D seismic data, and the program aims to evaluate key commercial parameters such as flow, pressure behavior, continuity, gas concentrations, deliverability and scalability. This follows the company's previously announced Natural Hydrogen discovery and independent laboratory confirmation, positioning MAX Power at the forefront of the emerging natural hydrogen sector.</p><p>In addition to the drilling program, MAX Power announced a six-month renewal of its investor awareness agreement with Emerging Markets Consulting, under which it will pay an additional $400,000 for strategic communications and investor awareness services. The company also granted incentive stock options to certain directors, officers and consultants to purchase up to an aggregate of 5,235,000 common shares under its omnibus equity incentive plan. These moves underscore MAX Power's commitment to advancing its projects while maintaining strong investor relations.</p><p>MAX Power is an innovative mineral and energy exploration company focused on the shift to decarbonization. The company's Lawson Discovery near Central Butte, Saskatchewan, represents Canada's first-ever subsurface Natural Hydrogen system confirmed through deep drilling with data validated by three independent labs. MAX Power has built dominant district-scale land positions across Saskatchewan with approximately <strong>1.3 million acres (521,000 hectares) of permits</strong> covering prime exploration ground prospective for large-volume accumulations of Natural Hydrogen. The company also holds a portfolio of properties in the United States and Canada focused on critical minerals, highlighted by a 2024 diamond drilling discovery at the Willcox Playa Lithium Project in southeast Arizona. MAX Power is committed to responsible exploration and development practices that prioritize environmental stewardship, meaningful community engagement, and strong corporate governance. For more information, visit <a href='https://ibn.fm/yj9WH'>https://ibn.fm/yj9WH</a>.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/57b17c1a635e23d40a8eb30689a7e996.35209.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/57b17c1a635e23d40a8eb30689a7e996.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//57b17c1a635e23d40a8eb30689a7e996'>MAX Power Launches Commercial Validation Drilling for Natural Hydrogen.</a></p></div>        </article>    ", "published": "2026-07-10T13:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/57b17c1a635e23d40a8eb30689a7e996.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/57b17c1a635e23d40a8eb30689a7e996.webp", "enclosure": "https://cdn.newsramp.app/banners/environment-energy-7.jpg", "site_handle": "ibn", "seo_description": "MAX Power Mining mobilizes drilling rig for commercial validation of natural hydrogen in Saskatchewan, targeting world's first large-scale discovery. Learn about the program and potential impact on clean energy.", "newsramp_curated": "https://newsramp.com/curated-news/max-power-launches-commercial-validation-drilling-for-natural-hydrogen/57b17c1a635e23d40a8eb30689a7e996"}, {"feed_item_id": 35205, "prhash_id": "6ea3fada7b4f2a266d1eb74565e56bee", "headline": "UraniumX Acquires Dieter Lake; IsoEnergy Takes Strategic Stake", "content": "        <article>        <h1>UraniumX Acquires Dieter Lake; IsoEnergy Takes Strategic Stake</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-1.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='UraniumX Acquires Dieter Lake; IsoEnergy Takes Strategic Stake'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>UraniumX acquires Dieter Lake with 24.4M lbs U3O8 historical estimate, gaining strategic partner IsoEnergy's 15.6% stake.</li>            <li>UraniumX issues 18M shares at $0.10 each and a 2% NSR to Consolidated Uranium for 100% of Dieter Lake.</li>            <li>UraniumX expands into Quebec, advancing uranium exploration for clean energy with minimal cash outlay.</li>            <li>Dieter Lake's historical estimate was prepared using the Thiessen polygon method on 2006 data, open for modern drilling.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it marks a significant strategic partnership in the uranium sector. IsoEnergy, owner of the world's highest-grade uranium deposit, is backing UraniumX with a substantial equity stake and board representation. For investors, this signals confidence in UraniumX's growth potential and the value of the Dieter Lake project, which could become a key uranium asset. The acquisition positions UraniumX as a multi-jurisdictional player, potentially increasing its appeal to institutional investors and providing leverage to rising uranium prices driven by global nuclear energy demand.</p>        <h2>Summary</h2>        <p><p>UraniumX Discovery Corp. (CSE: STMN) (OTCQB: STMXF) (FSE: Q7S) has entered into a definitive asset purchase agreement with Consolidated Uranium Inc., a wholly owned subsidiary of IsoEnergy Ltd., to acquire a 100% interest in the Dieter Lake uranium project in North-Central Quebec. The transaction, which involves no cash consideration, will see Consolidated Uranium receive 18 million common shares of UraniumX at a deemed price of $0.10 per share and a 2.0% net smelter returns royalty. Upon closing, IsoEnergy is expected to hold approximately 15.6% of UraniumX on a non-diluted basis, making it one of the company\u2019s largest shareholders with the right to nominate one director to the board. This strategic endorsement from a uranium leader underscores the significance of the deal.</p><p>Dieter Lake hosts a historical estimate of 19.3 million tonnes at 0.057% U3O8, containing approximately 24.4 million lbs U3O8. The property comprises 168 claims over approximately 8,106 hectares in North-Central Quebec, where uranium mineral exploration is permitted. The mineralization is traced over approximately 6 km of strike, open to the southwest, with additional targets generated by a 2025 heliborne magnetic survey and a 2023 alteration-mineral study. The majority of the property has seen little or no modern drilling, presenting significant expansion potential. UraniumX plans to advance the project toward a current mineral resource estimate through compilation, verification, and confirmation drilling.</p><p>The transaction aligns UraniumX with IsoEnergy, a leading uranium developer that owns the Hurricane deposit, described as the world\u2019s highest-grade published indicated uranium mineral resource. IsoEnergy\u2019s portfolio includes current and historical uranium resources across three tier-one jurisdictions, with permitted past-producing mines in Utah positioned for near-term production. The deal transforms UraniumX into a multi-jurisdiction Canadian uranium company with projects in both Saskatchewan and Quebec. As Esen Boldkhuu, CEO of UraniumX, stated, 'Dieter Lake will hand our shareholders a project with a historical estimate of 24.4 million pounds of U3O8, in a mineralized horizon that is still open, on ground that has seen little or no modern drilling.' The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary conditions.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/6ea3fada7b4f2a266d1eb74565e56bee.35205.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/6ea3fada7b4f2a266d1eb74565e56bee.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/isoenergy-to-become-strategic-shareholder-of-uraniumx-as-company-agrees-to-acquire-dieter-lake-uranium-project-7087621/6ea3fada7b4f2a266d1eb74565e56bee'>UraniumX Acquires Dieter Lake; IsoEnergy Takes Strategic Stake.</a></p></div>        </article>    ", "published": "2026-07-10T10:30:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/6ea3fada7b4f2a266d1eb74565e56bee.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/6ea3fada7b4f2a266d1eb74565e56bee.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-1.jpg", "site_handle": "newmediawire", "seo_description": "UraniumX Discovery Corp. acquires Dieter Lake uranium project from IsoEnergy subsidiary, gaining 24.4M lbs historical U3O8. IsoEnergy becomes 15.6% strategic shareholder with board rights. Multi-jurisdiction Canadian uranium play.", "newsramp_curated": "https://newsramp.com/curated-news/uraniumx-acquires-dieter-lake-isoenergy-takes-strategic-stake/6ea3fada7b4f2a266d1eb74565e56bee"}, {"feed_item_id": 35201, "prhash_id": "818f0980cee862998fe3a2dac9c6952f", "headline": "Western Star Hits 0.14% WO3 in Soil at Rowland Tungsten Property", "content": "        <article>        <h1>Western Star Hits 0.14% WO3 in Soil at Rowland Tungsten Property</h1>        <img src='https://cdn.newsramp.app/banners/science-2.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Western Star Hits 0.14% WO3 in Soil at Rowland Tungsten Property'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Western Star\u2019s 0.14% WO3 soil anomaly validates a low-cost vector to high-grade tungsten, giving early movers a strategic advantage.</li>            <li>Phase 1 soil geochemistry confirms tungsten-skarn signature over 1 km corridor, aligning with magnetic gradients to guide expanded sampling.</li>            <li>Western Star\u2019s exploration strengthens North America\u2019s domestic tungsten supply, reducing reliance on foreign critical minerals for a sustainable future.</li>            <li>First-ever soil survey at Rowland returned 1,425 ppm WO3, revealing a polymetallic skarn system with copper, molybdenum, and bismuth.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it demonstrates the potential of the Rowland Tungsten Property to become a significant domestic source of tungsten, a critical mineral essential for defense, aerospace, and high-tech industries. With the U.S. heavily reliant on imports, successful exploration could reduce supply chain vulnerabilities and support national security. For investors, the strong soil anomalies and immediate expansion program signal a de-risked path toward drill targets, offering a compelling entry point into a critical mineral play.</p>        <h2>Summary</h2>        <p><p>Western Star Resources Inc. has announced exceptional results from its Phase 1 soil-geochemistry program at the past-producing Rowland Tungsten Property in Elko County, Nevada. The program, which the company believes is the first-ever soil survey conducted by a public company at Rowland, returned a peak of 1,425 parts per million (ppm) tungsten trioxide (WO3) in soil, equivalent to 0.14% WO3, directly over a recently re-discovered historical working zone. Additional highlights include strong tungsten-in-soil values of up to 517 ppm and 504 ppm WO3 over the Rowland Main historical workings, along with coincident elevated levels of associated critical metals such as copper (up to 1,185 ppm), molybdenum (up to 35 ppm), bismuth (up to 5.2 ppm), and beryllium (up to 4.56 ppm). The anomalous soil results align closely with magnetic gradients identified by the company's UAV magnetic survey, which are interpreted to reflect lithological and structural contacts associated with the tungsten-skarn system. This validation of the targeting model has prompted Western Star to immediately mobilize an expanded soil program to extend the known zones and explore untested ground, with the goal of converting anomalies into ranked drill targets for a maiden drilling program. The company's President and CEO, Blake Morgan, emphasized the significance of the soil geochemistry as a low-cost vector to prospective skarn-contact zones and expressed confidence in the program's design.</p><p>The Phase 1 soil grid consisted of 93 samples collected at 25-meter spacing over the central Rowland workings corridor. The results indicate a coherent tungsten-skarn signature developed along a carbonate-intrusive contact, with potentially mineralized NE-SW structures. The peak value of 1,425 ppm WO3 was recorded at the X-3 site in the central zone, while a second cluster of high values overlies the Rowland Main workings to the south. The polymetallic skarn signature, including elevated copper, molybdenum, bismuth, and beryllium, confirms the presence of a reduced tungsten (W-Cu-Mo-Bi) skarn system, where tungsten-bearing fluids from a Cretaceous granite reacted with Ordovician\u2013Cambrian limestone. The company's CEO highlighted that the soils line up with contacts mapped by UAV magnetics, providing a strong vector for further exploration. An expanded multi-stage soil campaign will begin shortly to extend the known zones and search for new discoveries, with results to be integrated with geophysical data and field mapping to prioritize drill targets.</p><p>The Rowland property is interpreted as a reduced tungsten skarn, and the Phase 1 results have confirmed that soil geochemistry is an effective tool for highlighting prospective skarn-contact zones. The company has high confidence that the method can be used aggressively to expand known mineralized areas and identify new ones. Western Star Resources is focused on revitalizing North America's tungsten supply and is positioning itself to participate in the growing demand for secure domestic critical minerals. The company has also entered into an investor awareness agreement with Baystreet.ca Media Corp. for branding and consulting services. The scientific and technical information in this release has been reviewed by Jasper Mowatt, a Qualified Person as defined by NI 43-101. For more information, visit <a href='http://www.westernstarresources.com/'>www.westernstarresources.com</a>.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/818f0980cee862998fe3a2dac9c6952f.35201.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/818f0980cee862998fe3a2dac9c6952f.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/western-star-resources-reports-phase-1-soil-sampling-from-the-past-producing-rowland-tungsten-property-highlight-of-a-0-14-wo3-in-soil-result-7087620/818f0980cee862998fe3a2dac9c6952f'>Western Star Hits 0.14% WO3 in Soil at Rowland Tungsten Property.</a></p></div>        </article>    ", "published": "2026-07-10T07:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/818f0980cee862998fe3a2dac9c6952f.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/818f0980cee862998fe3a2dac9c6952f.webp", "enclosure": "https://cdn.newsramp.app/banners/science-2.jpg", "site_handle": "newmediawire", "seo_description": "Western Star Resources reports 0.14% WO3 in soil at Rowland Tungsten Property, validating skarn model and prompting expanded soil program for drill targeting.", "newsramp_curated": "https://newsramp.com/curated-news/western-star-hits-0-14-wo3-in-soil-at-rowland-tungsten-property/818f0980cee862998fe3a2dac9c6952f"}]}